컴퓨터 단층촬영(CT) 시장 : 제품 유형, 구성 요소, 용도, 최종 사용자, 모달리티별 - 세계 시장 예측(2026-2032년)

The Computed Tomography Market is projected to grow by USD 12.17 billion at a CAGR of 6.45% by 2032.

Computed tomography (CT) remains one of the most strategically important medical imaging modalities because it delivers rapid, high-resolution cross-sectional visualization for emergency medicine, oncology, cardiology, neurology, pulmonology, and image-guided interventions. Hospitals and imaging centers rely on CT scanners for time-sensitive diagnosis in trauma, stroke, pulmonary embolism, coronary artery disease, cancer staging, and post-treatment surveillance.

The computed tomography landscape is being shaped by the clinical need for faster throughput, lower radiation dose, improved image quality, and consistent diagnostic confidence. Demand is reinforced by aging populations, the rising global burden of noncommunicable diseases, and the continued expansion of advanced diagnostic imaging infrastructure across mature and emerging healthcare systems.

Innovation is increasingly centered on low-dose CT, spectral CT, dual-energy CT, wide-detector systems, portable CT, and photon-counting CT, alongside artificial intelligence-enabled reconstruction and workflow automation. For industry leaders, CT is no longer only a hardware category; it is an integrated ecosystem spanning scanners, detectors, software, service contracts, cloud connectivity, cybersecurity, and clinical decision support.

Transformative Shifts in the CT Landscape

The CT landscape is undergoing a structural shift from equipment replacement cycles toward digitally connected, protocol-driven imaging platforms. Healthcare providers are prioritizing systems that reduce scan time, standardize image acquisition, support enterprise imaging integration, and improve operational productivity across radiology departments.

A major transformation is the movement toward patient-centered and value-based imaging. Providers are under pressure to improve diagnostic yield while managing radiation exposure, staffing shortages, reimbursement scrutiny, and rising procedure volumes. This is accelerating adoption of dose-optimization tools, automated positioning, iterative and deep learning reconstruction, and standardized reporting workflows.

Another important shift is the diversification of CT use sites. While tertiary hospitals remain central to advanced applications such as cardiac CT, oncology staging, and stroke imaging, outpatient imaging networks and ambulatory care centers are expanding access to routine CT examinations. At the same time, sustainability, energy efficiency, uptime guarantees, lifecycle service models, and secure connectivity are becoming decisive procurement factors.

Cumulative Impact of Artificial Intelligence on CT

Artificial intelligence is creating cumulative value across the CT imaging chain, from patient positioning and protocol selection to image reconstruction, triage, segmentation, quantification, and structured reporting. AI-enabled reconstruction can support lower-dose scanning while preserving image quality, and AI triage tools can help flag urgent findings such as intracranial hemorrhage, pulmonary embolism, pneumothorax, and large vessel occlusion.

Regulatory momentum supports the long-term role of AI in CT. The U.S. FDA has authorized hundreds of AI-enabled medical devices across imaging and radiology, demonstrating that software is becoming a core differentiator for diagnostic platforms. However, real-world adoption depends on validated performance, clinical workflow fit, interoperability with PACS, RIS, and electronic health records, transparent governance, and continuous monitoring for bias and model drift.

The cumulative impact of AI is strongest where it improves measurable outcomes: reduced turnaround time, fewer repeat scans, improved radiologist productivity, lower radiation exposure, and more consistent quantitative assessment in oncology, cardiology, and lung disease. Vendors that combine CT hardware innovation with secure, explainable, and clinically validated AI are better positioned in competitive procurement cycles.

Key Regional Insights for Computed Tomography

Asia-Pacific is one of the most dynamic CT regions, supported by large patient populations, expanding hospital networks, and growing investment in diagnostic infrastructure. China, India, Japan, South Korea, and Australia are central to regional demand, with Japan and South Korea demonstrating advanced adoption of high-end CT systems and China and India showing strong volume-led demand across public and private care settings.

North America remains a technology-leading region, driven by high imaging utilization, a broad installed base, advanced clinical protocols, and early adoption of AI-enabled imaging. The United States anchors regional demand through extensive hospital networks, outpatient imaging centers, and regulatory pathways that support advanced CT and imaging software commercialization, while Canada emphasizes access, quality, public procurement, and modernization of diagnostic capacity.

Latin America shows growing CT demand as Brazil and Mexico expand diagnostic capacity and private healthcare investment. The region faces budget constraints and uneven access, but demand is supported by urban hospital modernization, oncology care expansion, and the need for emergency imaging. Europe remains a mature and regulation-driven region, with Germany, France, Italy, Spain, and the United Kingdom emphasizing quality standards, dose management, sustainability, interoperability, and compliance with medical device regulations.

The Middle East is investing in advanced imaging as part of healthcare modernization strategies, especially across Gulf countries where specialty hospitals, trauma care, oncology programs, and medical tourism initiatives support premium CT adoption. Africa remains underpenetrated compared with other regions, but long-term opportunities are tied to public health investment, donor-supported infrastructure, urban hospital development, workforce training, and scalable service models that address maintenance and affordability.

Key Group Insights Across Major Economic Blocs

ASEAN demand is supported by hospital expansion, medical tourism, and rising chronic disease diagnosis across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The group presents a dual-market structure, with advanced urban hospitals adopting premium CT systems while broader healthcare networks require cost-effective, reliable platforms with strong service support and technologist training.

The GCC is a high-investment healthcare group where Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman are expanding specialty care, trauma services, oncology programs, and digital health infrastructure. CT procurement in the GCC is closely linked to national healthcare transformation plans, private hospital growth, medical tourism, and demand for premium imaging technologies that support rapid diagnosis and integrated care pathways.

The European Union is shaped by harmonized regulatory expectations, radiation safety principles, public procurement discipline, and strong emphasis on interoperability, cybersecurity, and sustainability. EU healthcare systems continue to invest in CT modernization, but purchasing decisions are influenced by lifecycle cost, dose optimization, compliance with evolving medical device and data protection frameworks, and the need to improve diagnostic access.

BRICS countries represent scale-driven CT opportunities, led by China and India and supported by Brazil, Russia, and South Africa. These markets combine large disease burdens with uneven imaging access, creating demand for both high-end tertiary systems and value-oriented scanners. G7 countries remain critical for innovation, clinical validation, and premium adoption because they combine advanced healthcare infrastructure with strong research institutions. NATO countries, particularly in North America and Europe, also prioritize resilient healthcare infrastructure, emergency readiness, secure medical technology supply chains, and interoperable digital systems.

Key Country Insights in Computed Tomography

The United States remains a leading country for advanced CT adoption, supported by high imaging utilization, outpatient imaging networks, emergency medicine demand, and rapid commercialization of AI-enabled radiology tools. Canada's CT environment is shaped by public healthcare priorities, wait-time management, quality standards, and investments in modern imaging capacity, while Mexico benefits from private hospital expansion, urban diagnostic growth, and cross-border healthcare demand.

Brazil leads Latin American CT activity through its large hospital base, oncology needs, and private healthcare sector, while the United Kingdom emphasizes imaging access, National Health Service capacity planning, and diagnostic center expansion. Germany remains a European imaging powerhouse with strong hospital infrastructure and demand for premium CT systems. France prioritizes quality, radiation protection, and national imaging modernization, while Italy and Spain continue to invest in equipment renewal, oncology imaging, emergency care, and regional healthcare upgrades.

Russia maintains demand for CT across large public healthcare networks and regional hospital systems, although procurement dynamics are influenced by economic and supply-chain conditions. China is a scale leader, combining domestic manufacturing capacity, public hospital investment, and rapid adoption of advanced imaging in major cities. India shows strong potential due to expanding private diagnostics, medical tourism, and rising chronic disease detection, although affordability, access, and workforce availability remain important constraints.

Japan is a mature, high-utilization CT environment with strong adoption of advanced scanner configurations and an aging population that supports sustained diagnostic demand. Australia emphasizes quality, access, and advanced imaging across public and private systems, while South Korea stands out for technologically advanced hospitals, strong digital health adoption, and a competitive private medical sector.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize CT platforms that combine image quality, dose efficiency, and workflow automation with measurable economic value. Procurement decisions increasingly depend on total cost of ownership, uptime, service responsiveness, cybersecurity, energy efficiency, and compatibility with enterprise imaging ecosystems.

Vendors should invest in clinically validated AI that solves operational pain points rather than adding disconnected features. High-impact areas include automated protocoling, low-dose reconstruction, urgent finding triage, lesion measurement, cardiac analysis, lung nodule assessment, and structured reporting. Clear evidence on productivity gains, diagnostic accuracy, and patient safety is essential for adoption.

Healthcare providers should standardize CT protocols, monitor radiation dose, train technologists on advanced capabilities, and integrate CT data into multidisciplinary care pathways. Market participants should develop differentiated strategies for mature and emerging regions, balancing premium innovation with affordable systems, financing models, remote service, preventive maintenance, and local training.

Research Methodology

This executive summary is developed using a structured research methodology that combines secondary research, data triangulation, and expert interpretation. Inputs include publicly available information from health authorities, regulatory agencies, peer-reviewed literature, hospital procurement trends, clinical guideline bodies, and international organizations such as WHO, OECD, FDA, European Commission sources, and national health agencies.

The analysis evaluates CT demand drivers, technology trends, regional adoption patterns, regulatory influences, and competitive positioning without relying on market sizing, share estimates, or forecasts. Findings are validated through cross-comparison of multiple credible sources to avoid reliance on isolated claims. Emphasis is placed on verifiable signals such as disease burden, imaging utilization, healthcare infrastructure investment, AI device authorization trends, installed-base modernization, and replacement demand.

The methodology is designed to support executive decision-making by connecting clinical need, technology innovation, reimbursement pressure, regulatory requirements, and regional readiness. Qualitative insights are interpreted through the lens of practical commercial relevance for manufacturers, software developers, healthcare providers, investors, and channel partners.

Conclusion

Computed tomography is entering a new phase defined by intelligent imaging, dose-conscious care, faster workflows, and integrated diagnostic ecosystems. Demand is supported by the global burden of cancer, cardiovascular disease, neurological emergencies, trauma, and chronic respiratory conditions, all of which require timely and accurate imaging.

The most competitive CT strategies align hardware innovation with AI, service reliability, interoperability, cybersecurity, and region-specific affordability. Mature regions reward premium performance, automation, and enterprise integration, while emerging regions require scalable, durable, and cost-effective CT solutions supported by training and reliable service infrastructure.

As healthcare systems pursue earlier diagnosis and more efficient care delivery, CT remains central to modern medical imaging. Organizations that demonstrate clinical value, operational efficiency, radiation safety, and trusted technology governance are best positioned to build resilient long-term advantage.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Computed Tomography Market, by Product Type

• 7.1. Multi Slice
  • 7.1.1. 16 Slices
  • 7.1.2. 64 Slices
  • 7.1.3. Above 64 Slices
• 7.2. Single Slice

8. Computed Tomography Market, by Component

• 8.1. Hardware
• 8.2. Services
• 8.3. Software

9. Computed Tomography Market, by Application

• 9.1. Cardiology
  • 9.1.1. Calcium Scoring
  • 9.1.2. Cardiac Structure Assessment
  • 9.1.3. Coronary CT Angiography (CTA)
• 9.2. Gastroenterology
• 9.3. Neurology
  • 9.3.1. Brain perfusion Studies
  • 9.3.2. Brain Tumor Assessment
  • 9.3.3. Skull Fractures
  • 9.3.4. Stroke Evaluation
• 9.4. Oncology
  • 9.4.1. Biopsy Guidance
  • 9.4.2. Staging
  • 9.4.3. Treatment Monitoring
  • 9.4.4. Tumor Detection
• 9.5. Orthopedics
• 9.6. Trauma

10. Computed Tomography Market, by End User

• 10.1. Ambulatory Surgery Centers
• 10.2. Clinics
• 10.3. Diagnostic Imaging Centers
• 10.4. Hospitals

11. Computed Tomography Market, by Modality

• 11.1. Stationary
• 11.2. Portable

12. Computed Tomography Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Computed Tomography Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Computed Tomography Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Allengers Medical Systems Ltd.
• 16.2. Arineta Ltd.
• 16.3. Basda Medical Apparatus Co., Ltd.
• 16.4. Bruker Corporation
• 16.5. Canon Medical Systems Corporation
• 16.6. Carestream Health, Inc.
• 16.7. Fujifilm Holdings Corporation
• 16.8. GE HealthCare Technologies Inc.
• 16.9. Hologic, Inc.
• 16.10. Izotropic Corporation
• 16.11. J. Morita Corporation
• 16.12. Koning Corporation
• 16.13. Koninklijke Philips N.V.
• 16.14. MARS Bioimaging Ltd.
• 16.15. MinFound Medical Systems Co., Ltd.
• 16.16. MR Solutions Ltd.
• 16.17. NeuroLogica Corp.
• 16.18. Neusoft Medical Systems Co., Ltd.
• 16.19. Planmeca Oy
• 16.20. Shenzhen Anke High-tech Co., Ltd.
• 16.21. Shimadzu Corporation
• 16.22. Siemens Healthineers AG
• 16.23. Trivitron Healthcare
• 16.24. United Imaging Healthcare Co., Ltd.
• 16.25. Vatech Co., Ltd.
• 16.26. Xoran Technologies, Inc.